These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36704927)

  • 1. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
    Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
    Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.
    Pasvolsky O; Ghanem S; Milton DR; Rauf M; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Aljawai Y; Khan HN; Kebriaei P; Lee HC; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Blood Cancer J; 2024 Jan; 14(1):4. PubMed ID: 38199987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real-world Swedish population receiving modern treatment.
    Lemonakis K; Olsson-Arvidsson L; Karlsson C; Johansson B; Hansson M
    Eur J Haematol; 2023 Sep; 111(3):391-399. PubMed ID: 37271732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
    Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
    Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
    [No Abstract]   [Full Text] [Related]  

  • 9. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
    Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
    Shah GL; Landau H; Londono D; Devlin SM; Kosuri S; Lesokhin AM; Lendvai N; Hassoun H; Chung DJ; Koehne G; Jhanwar SC; Landgren O; Levine R; Giralt SA
    Leuk Lymphoma; 2017 Aug; 58(8):1823-1831. PubMed ID: 28078910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
    Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
    Yan J; Zhou DM; Shao XY; Xu Y; Chen B
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
    [No Abstract]   [Full Text] [Related]  

  • 13. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
    Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
    J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.
    Xu J; Xu T; Yang Y; Wang W; Li J; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P
    Leuk Lymphoma; 2020 Oct; 61(10):2351-2364. PubMed ID: 32519901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.
    Yang P; Chen H; Liang X; Xu W; Yu S; Huang W; Yi X; Guo Q; Tian M; Yue T; Li M; Zhang Y; Zhang M; Yan Y; Hu Z; Kumar SK; Zhou F; Dai Y; Jin F
    Am J Hematol; 2023 Feb; 98(2):251-263. PubMed ID: 36309982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
    D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
    J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
    Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
    Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
    Abdallah N; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Rajkumar SV; Kumar SK
    Blood Adv; 2020 Aug; 4(15):3509-3519. PubMed ID: 32750129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
    Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
    Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.